Mark Leuchtenberger
Chairman at NEUROSENSE THERAPEUTICS LTD.
Net worth: 80 640 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sumi Biswas | F | - |
Spybiotech Ltd.
 Spybiotech Ltd. BiotechnologyHealth Technology Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom. | 7 years |
| Alon Ben-Noon | M | 45 | 7 years | |
| Eddie J. Gray | M | 64 |
Spybiotech Ltd.
Spybiotech Ltd. BiotechnologyHealth Technology Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom. | 1 years |
| Vien Phan | M | - |
Spybiotech Ltd.
Spybiotech Ltd. BiotechnologyHealth Technology Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom. | - |
| Christine Pellizzari | F | 56 | 3 years | |
| Cary Claiborne | M | 64 | 3 years | |
| Caren Deardorf | F | 59 | 3 years | |
| Neal M. Farber | M | - |
NeuroHealing Pharmaceuticals, Inc.
 NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | - |
| Roger Beahm | M | - |
Wake Forest University
| - |
| David N. LaMond | M | - |
Wake Forest University
| - |
| Or Eisenberg | M | 43 | 3 years | |
| Oron Yacoby-Zeevi | M | 63 | - | |
| Stephen R. Berlin | M | - |
Wake Forest University
| - |
| Mark Howarth | M | - |
Spybiotech Ltd.
Spybiotech Ltd. BiotechnologyHealth Technology Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom. | 7 years |
| Matthew S. Cullinan | M | - |
Wake Forest University
| - |
| Ethel M. Koczon | F | - | 9 years | |
| Michael Batalia | M | - |
Wake Forest University
| - |
| Louis Kucera | M | - |
Wake Forest University
| 54 years |
| Daniel L. Menichella | M | 64 |
Spybiotech Ltd.
Spybiotech Ltd. BiotechnologyHealth Technology Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom. | - |
| Darryl L. Landis | M | - |
Wake Forest University
| - |
| Boris Pasche | M | 63 |
Wake Forest University
| - |
| Harold Rosser | M | 75 |
Wake Forest University
| - |
| Simon J Draper | M | - |
Spybiotech Ltd.
Spybiotech Ltd. BiotechnologyHealth Technology Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom. | 7 years |
| Nedira Salzman-Frenkel. | F | - | 2 years | |
| James Wong | M | - |
Spybiotech Ltd.
Spybiotech Ltd. BiotechnologyHealth Technology Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom. | - |
| Ferenc Tracik | M | 60 | 3 years | |
| Greg Keeley | M | - |
Wake Forest University
| - |
| James Becton | M | - |
Wake Forest University
| - |
| Louise Broyhill | F | - |
Wake Forest University
| - |
| Janice Calloway | F | - |
Wake Forest University
| - |
| Lisbeth Evans | F | - |
Wake Forest University
| - |
| Elizabeth Domenech | F | - |
Wake Forest University
| - |
| Martin Guthold | M | - |
Wake Forest University
| - |
| Stan Meiburg | M | - |
Wake Forest University
| - |
| Diana Shtossel | F | - | 2 years | |
| Irit Shefer | F | - | 2 years | |
| Shiran Zimri | M | - | 4 years | |
| Jane Brightwell | F | - |
Wake Forest University
| - |
| Brig Sorber | M | - |
Wake Forest University
| - |
| Revital Mandil–Levin | M | 49 | 2 years | |
| H. Culp | M | 60 |
Wake Forest University
| - |
| William G. Ward | M | 70 |
Wake Forest University
| - |
| Eric Wiseman | M | 68 |
Wake Forest University
| - |
| Matthew King | M | 65 |
Wake Forest University
| - |
| Elkan R. Gamzu | M | 81 |
NeuroHealing Pharmaceuticals, Inc.
NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | - |
| Scott E. Reed | M | 75 |
Wake Forest University
| - |
| David W. Dupree | M | 71 |
Wake Forest University
| - |
| Ronald E. Deal | M | 80 |
Wake Forest University
| 21 years |
| Thomas W. Bunn | M | 71 |
Wake Forest University
| 14 years |
| William L. Marks | M | 80 |
Wake Forest University
| - |
| Curtis Farmer | M | 61 |
Wake Forest University
| - |
| Cantey M. Ergen | F | 68 |
Wake Forest University
| 5 years |
| Adelaide Sink | F | 75 |
Wake Forest University
| - |
| David I. Gwynne | M | - |
NeuroHealing Pharmaceuticals, Inc.
NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | 40 years |
| Andrew J. Schindler | M | 79 |
Wake Forest University
| - |
| William Greene | M | - |
Wake Forest University
| - |
| Jack Lowden | M | 66 |
Wake Forest University
| - |
| William I. Ramage | M | - | 11 years | |
| Peter Carlson | M | 60 |
Wake Forest University
| - |
| Elizabeth Amato | F | 67 |
Wake Forest University
| - |
| Troy McConnell | M | - |
Wake Forest University
| - |
| Kim Westmoreland | M | - |
Wake Forest University
| - |
| Charles Iacovou | M | - |
Wake Forest University
| - |
| Elizabeth J. Gatewood | M | - |
Wake Forest University
| 20 years |
| Stephen L. Wallenhaupt | M | - |
Wake Forest University
| - |
| Joshua D. Hamermesh | M | 51 |
NeuroHealing Pharmaceuticals, Inc.
NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | 10 years |
| Donald C. Ingram | M | - |
Wake Forest University
| - |
| Patrick Thean | M | - |
Wake Forest University
| - |
| Daniel M. Delen | M | 58 |
Wake Forest University
| - |
| C. Nye | M | 61 |
Wake Forest University
| - |
| Mitesh B. Shah | M | 54 |
Wake Forest University
| - |
| Lars Nelson | M | 65 |
Wake Forest University
| - |
| Ekaterina Smirnyagina | M | 58 |
Spybiotech Ltd.
Spybiotech Ltd. BiotechnologyHealth Technology Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom. | - |
| Hagit Binder | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ronald Guido | M | 67 |
Eterna Therapeutics LLC
 Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | 3 years |
| George Eldridge | M | 61 |
Targanta Therapeutics Corp.
 Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ.
Therion Biologics Corp.
 Therion Biologics Corp. Pharmaceuticals: MajorHealth Technology Therion Biologics Corp. developed therapeutic vaccines for cancer patients. The company was founded on May 5, 1991 and was headquartered in Cambridge, MA. | 7 years |
| Mark J. Fitzpatrick | M | 61 | 6 years | |
| Roy R. Lobb | M | - |
Mercator Therapeutics, Inc.
 Mercator Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mercator Therapeutics develops novel cancer drugs. It is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. The company was founded by Wadih Arap, Renata Pasqualini, Roy Lobb, Mark Leuchtenberger, and Christopher Guiffre in 2009 is headquartered in Wellesley, MA. | 3 years |
| Garen Bohlin | M | 76 |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | 10 years |
| Drew Enamait | M | 50 | 6 years | |
| Tara Mccarthy | F | 50 | - | |
| Dror Brandwein | M | - | 3 years | |
| Daniel Char | M | 63 |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | 1 years |
| Vincent J. Miles | M | 73 | 3 years | |
| Jason Fredette | M | - | 1 years | |
| Christopher Guiffre | M | 56 |
Mercator Therapeutics, Inc.
Mercator Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mercator Therapeutics develops novel cancer drugs. It is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. The company was founded by Wadih Arap, Renata Pasqualini, Roy Lobb, Mark Leuchtenberger, and Christopher Guiffre in 2009 is headquartered in Wellesley, MA. | 3 years |
| Chaime Orlev | M | 53 | 6 years | |
| John Thero | M | 63 | 6 years | |
| James Tobin | M | 79 | 1 years | |
| Jay Venkatesan | M | 52 |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | 1 years |
| Eric M. Gordon | M | 78 |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | 2 years |
| Thomas Schuetz | M | 63 |
Therion Biologics Corp.
Therion Biologics Corp. Pharmaceuticals: MajorHealth Technology Therion Biologics Corp. developed therapeutic vaccines for cancer patients. The company was founded on May 5, 1991 and was headquartered in Cambridge, MA. | 3 years |
| Stéphane Bancel | M | 51 |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | 1 years |
| Pierre E. G. Etienne | M | 76 |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | 4 years |
| Wadih Arap | M | - |
Mercator Therapeutics, Inc.
Mercator Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mercator Therapeutics develops novel cancer drugs. It is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. The company was founded by Wadih Arap, Renata Pasqualini, Roy Lobb, Mark Leuchtenberger, and Christopher Guiffre in 2009 is headquartered in Wellesley, MA. | 3 years |
| Colleen Wilson | F | 47 |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | 2 years |
| Walter Ogier | M | 67 |
IRX Therapeutics, Inc.
 IRX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology IRX Therapeutics, Inc. provides pharmaceutical products. Its therapies are designed to target and restore the immune system in order to improve a patient's response to next-generation cancer vaccines and novel targeted therapeutics. The company was founded in 1994 and is headquartered in New York, NY. | - |
| Anand Varadan | M | 57 | 1 years | |
| John Gustofson | M | - |
Therion Biologics Corp.
Therion Biologics Corp. Pharmaceuticals: MajorHealth Technology Therion Biologics Corp. developed therapeutic vaccines for cancer patients. The company was founded on May 5, 1991 and was headquartered in Cambridge, MA. | 2 years |
| Lynn Sadowski Mason | F | 45 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 79 | 79.00% |
| Israel | 13 | 13.00% |
| United Kingdom | 8 | 8.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mark Leuchtenberger
- Personal Network
